Cargando…
Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression
During the recent COVID-19 pandemic, the rapidly progressive shortage of intravenous sedative drugs led numerous intensive care units to look for potential alternatives in patients requiring mechanical ventilation for severe acute respiratory distress syndrome (ARDS). Inhalational sedation using the...
Autores principales: | Dupuis, Camie, Robert, Arnaud, Gerard, Ludovic, Morelle, Johann, Laterre, Pierre-François, Hantson, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933092/ https://www.ncbi.nlm.nih.gov/pubmed/35310519 http://dx.doi.org/10.1155/2022/3312306 |
Ejemplares similares
-
Sevoflurane: Nephrogenic diabetes insipidus following off-label use: case report
Publicado: (2022) -
Sevoflurane and nephrogenic diabetes insipidus on the rise: copeptin to the rescue?
por: Honore, Patrick M., et al.
Publicado: (2019) -
Sevoflurane: Nephrogenic diabetes insipidus: 2 case reports
Publicado: (2021) -
Novel compound aquaporin 2 mutations in nephrogenic diabetes insipidus
por: Liberatore, Raphael D., et al.
Publicado: (2012) -
Molecular Characterization of an Aquaporin−2 Mutation Causing Nephrogenic Diabetes Insipidus
por: Li, Qian, et al.
Publicado: (2021)